{"hands_on_practices": [{"introduction": "The immune system uses distinct cellular pathways to process antigens from intracellular versus extracellular threats, dictating whether a CD4+ or CD8+ T cell response is triggered. This exercise explores the fundamental dichotomy between the MHC class I and MHC class II antigen presentation pathways by challenging you to analyze a pathogen's immune evasion strategy. By reasoning through this scenario, you will develop a deeper understanding of how these pathways function and how their disruption impacts the adaptive immune response [@problem_id:4605161].", "problem": "A professional research team is evaluating the immune response to a newly identified intracellular bacterium that resides stably within phagosomes of dendritic cells (DCs) and macrophages. The organism secretes a factor that specifically prevents any protein flux from the phagosome into the cytosol. The team wants to predict how this constraint will alter priming of naive T cells and how to compensate for any deficiency.\n\nUse as a fundamental base the established antigen processing and presentation pathways: endogenously synthesized proteins are degraded by cytosolic proteasomes and their peptides are transported by the Transporter associated with Antigen Processing (TAP) into the Endoplasmic Reticulum (ER) for loading onto Major Histocompatibility Complex (MHC) class I, which is recognized by CD8+ T cells; exogenous proteins internalized into endosomes or phagosomes are processed by endosomal and lysosomal proteases and loaded onto MHC class II, which is recognized by CD4+ T cells; and cross-presentation of exogenous antigens on MHC class I occurs via either a cytosolic route (phagosome-to-cytosol export, proteasomal degradation, and TAP-dependent ER loading) or a vacuolar route (processing and loading within endosomal compartments onto MHC class I without cytosolic transport).\n\nGiven the pathogen’s residence in phagosomes and its active blockade of phagosome-to-cytosol transport, which option best predicts the impact on CD8+ versus CD4+ T cell priming, and proposes a scientifically sound rescue strategy?\n\nA. CD8+ priming will be diminished because cytosolic cross-presentation is disabled, while CD4+ priming via MHC class II remains relatively intact; rescue by vaccinating with a recombinant viral vector encoding the pathogen’s antigen to drive endogenous expression and MHC class I presentation in DC.\n\nB. CD8+ priming will be enhanced due to prolonged phagosomal retention of antigen, while CD4+ priming will be reduced; rescue by adding a Toll-like receptor (TLR) agonist alone to increase co-stimulation.\n\nC. Both CD8+ and CD4+ priming will be markedly reduced; rescue by pharmacologically inhibiting the proteasome to preserve antigen and increase availability for MHC class I loading.\n\nD. CD8+ priming will be unaffected because vacuolar cross-presentation compensates fully, and CD4+ priming will be unchanged; no rescue is necessary.", "solution": "The user requires a critical validation of the provided problem statement, followed by a detailed solution and evaluation of the given options.\n\n### Step 1: Extract Givens\n\n1.  **Pathogen:** An intracellular bacterium.\n2.  **Location:** Resides stably within phagosomes of dendritic cells (DC) and macrophages.\n3.  **Pathogen Action:** Secretes a factor that specifically prevents any protein flux from the phagosome into the cytosol.\n4.  **Task:** Predict the impact on priming of naive CD8+ versus CD4+ T cells and propose a rescue strategy.\n5.  **Fundamental Principles Provided:**\n    *   **MHC Class I Pathway (Endogenous):** Cytosolic proteins $\\rightarrow$ proteasome degradation $\\rightarrow$ Transporter associated with Antigen Processing (TAP) transport to Endoplasmic Reticulum (ER) $\\rightarrow$ loading onto Major Histocompatibility Complex (MHC) class I $\\rightarrow$ recognition by CD8+ T cells.\n    *   **MHC Class II Pathway (Exogenous):** Proteins in endosomes/phagosomes $\\rightarrow$ endosomal/lysosomal protease degradation $\\rightarrow$ loading onto MHC class II $\\rightarrow$ recognition by CD4+ T cells.\n    *   **Cross-Presentation (Exogenous Antigen on MHC Class I):** Occurs via two routes:\n        *   **Cytosolic Route:** Phagosome-to-cytosol protein export $\\rightarrow$ proteasomal degradation $\\rightarrow$ TAP-dependent ER loading.\n        *   **Vacuolar Route:** Processing and loading of peptides onto MHC class I occurs within endosomal/phagosomal compartments, bypassing the cytosol and TAP.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement will now be assessed for validity.\n\n*   **Scientific Grounding:** The problem is firmly rooted in fundamental, well-established principles of cellular immunology and microbiology. The antigen processing pathways described for MHC class I and MHC class II, as well as the concept of cross-presentation (including cytosolic and vacuolar routes), are cornerstones of modern immunology. The scenario of a pathogen evolving mechanisms to subvert these pathways (e.g., by blocking phagosome-to-cytosol transport) is a realistic and extensively studied phenomenon in host-pathogen interactions. There are no violations of scientific principles.\n*   **Well-Posed:** The problem is clearly defined. It presents a specific scenario (a bacterium with a defined immune evasion mechanism) and asks for a prediction of the immunological consequences and a potential therapeutic intervention. The \"fundamental base\" provides the exact set of rules needed to logically deduce the outcome, making the problem self-contained and solvable.\n*   **Objective:** The language is technical, precise, and devoid of ambiguity or subjectivity. All terms used (MHC class I, MHC class II, phagosome, proteasome, TAP, etc.) have rigorous, universally accepted definitions in the field of immunology.\n\nThe problem statement is scientifically sound, well-posed, and objective. It does not exhibit any of the flaws listed in the validation criteria (e.g., factual unsoundness, incompleteness, ambiguity). Therefore, it is deemed valid.\n\n### Step 3: Verdict and Action\n\nThe problem is **valid**. Proceeding to the solution.\n\n### Derivation of the Solution\n\nThe problem requires an analysis of antigen presentation in the context of a specific pathogen-induced block.\n\n1.  **Analysis of the CD4+ T Cell Response (MHC Class II Pathway):**\n    *   The bacterium and its proteins are located within the phagosome. This compartment is part of the endo-lysosomal system.\n    *   The canonical MHC class II pathway processes exogenous antigens that are present in such compartments. Phagosomal proteases (e.g., cathepsins) degrade the bacterial proteins into peptides.\n    *   These peptides are then loaded onto MHC class II molecules within a specialized compartment (the MIIC/CIIV).\n    *   The pathogen's specific action is blocking protein flux *out of* the phagosome into the cytosol. This action does not interfere with the processes *within* the phagosome that lead to MHC class II loading.\n    *   Therefore, the presentation of bacterial antigens on MHC class II molecules and the subsequent priming of naive CD4+ T cells should remain largely intact.\n\n2.  **Analysis of the CD8+ T Cell Response (MHC Class I Pathway via Cross-Presentation):**\n    *   Since the bacterium is an exogenous antigen (internalized into a phagosome), priming of CD8+ T cells requires a process called cross-presentation, where the exogenous antigen is presented on MHC class I molecules.\n    *   The problem explicitly describes two routes for cross-presentation: cytosolic and vacuolar.\n    *   The pathogen's secreted factor \"prevents any protein flux from the phagosome into the cytosol.\"\n    *   This directly and completely abrogates the **cytosolic route** of cross-presentation, which depends on antigens moving from the phagosome to the cytosol to access the proteasome and TAP transporter.\n    *   The **vacuolar route** of cross-presentation, which does not require cytosolic transport, theoretically remains functional. However, the cytosolic route is a major pathway for cross-presentation of many particulate and soluble antigens. Its complete blockade is expected to cause a significant reduction in the overall efficiency of cross-presentation. It is highly unlikely that the vacuolar route could \"fully compensate\" for the loss of the cytosolic one.\n    *   Consequently, the priming of naive CD8+ T cells will be substantially **diminished** or impaired.\n\n3.  **Evaluation of a Rescue Strategy:**\n    *   The core deficit is the inability of bacterial antigens to access the endogenous MHC class I processing machinery (proteasome and TAP) due to the phagosomal blockade.\n    *   A successful rescue strategy must bypass this block. The goal is to introduce the bacterial antigen directly into the cytosol of an antigen-presenting cell, such as a DC.\n    *   If a bacterial antigen is synthesized *de novo* within the cytosol, it will be treated as an endogenous protein. It will be naturally targeted for degradation by the proteasome, and the resulting peptides will be transported by TAP into the ER for loading onto MHC class I.\n    *   Using a **recombinant viral vector** (e.g., an adenovirus or modified vaccinia virus) that encodes a bacterial antigen is a classic and effective method to achieve this. The virus infects the DC, and the host cell's translational machinery synthesizes the bacterial protein in the cytosol, thus feeding it directly into the canonical MHC class I pathway. This strategy completely circumvents the phagosomal location of the bacterium and its immune evasion mechanism.\n\n### Option-by-Option Analysis\n\n**A. CD8+ priming will be diminished because cytosolic cross-presentation is disabled, while CD4+ priming via MHC class II remains relatively intact; rescue by vaccinating with a recombinant viral vector encoding the pathogen’s antigen to drive endogenous expression and MHC class I presentation in DC.**\n*   **Impact Analysis:** This statement is fully consistent with the derivation above. It correctly identifies that the blockade of phagosome-to-cytosol transport disables the cytosolic cross-presentation pathway, leading to diminished CD8+ T cell priming. It also correctly concludes that the MHC class II pathway, which operates within the phagolysosomal system, remains intact.\n*   **Rescue Strategy:** The proposed rescue—using a viral vector to express the antigen endogenously—is a scientifically sound and precise solution to the identified deficit. It directly bypasses the pathogen's blockade.\n*   **Verdict:** **Correct**.\n\n**B. CD8+ priming will be enhanced due to prolonged phagosomal retention of antigen, while CD4+ priming will be reduced; rescue by adding a Toll-like receptor (TLR) agonist alone to increase co-stimulation.**\n*   **Impact Analysis:** This is incorrect. Blocking antigen export to the cytosol prevents its access to the primary machinery for cross-presentation (proteasome/TAP), thus a reduction, not an enhancement, of CD8+ priming is expected. The claim of reduced CD4+ priming is also baseless; if anything, prolonged antigen retention in the phagosome could enhance MHC class II presentation.\n*   **Rescue Strategy:** A TLR agonist provides \"Signal 2\" (co-stimulation) for T cell activation. However, it cannot compensate for a lack of \"Signal 1\" (peptide-MHC presentation). Without antigen presentation on MHC class I, increasing co-stimulation will not rescue the CD8+ T cell response.\n*   **Verdict:** **Incorrect**.\n\n**C. Both CD8+ and CD4+ priming will be markedly reduced; rescue by pharmacologically inhibiting the proteasome to preserve antigen and increase availability for MHC class I loading.**\n*   **Impact Analysis:** The claim that CD4+ priming will be reduced is incorrect, as the MHC class II pathway is unaffected.\n*   **Rescue Strategy:** This proposal is fundamentally flawed. The proteasome is essential for generating peptides from cytosolic proteins for loading onto MHC class I. Inhibiting the proteasome would *prevent*, not enhance, MHC class I presentation for both the endogenous and the cytosolic cross-presentation pathways. This strategy would be counterproductive.\n*   **Verdict:** **Incorrect**.\n\n**D. CD8+ priming will be unaffected because vacuolar cross-presentation compensates fully, and CD4+ priming will be unchanged; no rescue is necessary.**\n*   **Impact Analysis:** The assertion that vacuolar cross-presentation \"compensates fully\" is a very strong claim and is immunologically improbable. The cytosolic pathway is a major contributor, and its loss would almost certainly result in a diminished, not unaffected, CD8+ T cell response. While the vacuolar pathway exists, it is unlikely to be so efficient as to render the loss of the cytosolic pathway negligible.\n*   **Rescue Strategy:** Because the impact assessment is flawed, the conclusion that no rescue is necessary is also incorrect. A diminished CD8+ T cell response to an intracellular bacterium is a significant immunological defect.\n*   **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4605161"}, {"introduction": "Having explored the cellular logistics of antigen presentation, we now zoom in on the critical molecular interaction: the binding of a peptide to an MHC class II molecule. This practice focuses on the biophysical principles governing binding affinity, particularly the role of \"anchor\" residues and their chemical compatibility with the pockets of the MHC binding groove. You will learn not only to predict the impact of a mutation but also to design the definitive experiment to test your hypothesis, a core skill in biomedical science [@problem_id:4605128].", "problem": "A bacterial protein yields the peptide sequence \"AAVFYLMGRTKDSNN\" that is isolated from the surface of antigen-presenting cells after infection and found associated with Human Leukocyte Antigen (HLA) class II molecules. Using motif scanning and truncation analysis, you identify a likely class II binding register with a $9$-residue core, \"VFYLMGRTK\", in which the phenylalanine (F) occupies the P$1$ position of the binding core. The allele under study is HLA-DRB1*04:01, a Major Histocompatibility Complex (MHC) class II molecule whose P$1$ pocket is known to be deep and largely hydrophobic. You engineer a single substitution at P$1$ in the peptide core, replacing phenylalanine (F) with aspartate (D), while keeping all other residues unchanged.\n\nBased on first principles of MHC class II peptide binding, predict the effect of this P$1$ substitution on binding to HLA-DRB1*04:01 and select the most appropriate experimental assay to directly validate your prediction.\n\nA. The F$\\rightarrow$D substitution at P$1$ will markedly reduce peptide binding to HLA-DRB1*04:01 due to loss of a hydrophobic anchor in a hydrophobic pocket; validate by an in vitro competitive binding assay using purified HLA-DRB1*04:01 and a labeled high-affinity reference peptide to measure the half-maximal inhibitory concentration ($IC_{50}$).\n\nB. The F$\\rightarrow$D substitution at P$1$ will increase peptide binding to HLA-DRB1*04:01 by enabling a favorable salt bridge within the P$1$ pocket; validate by a Major Histocompatibility Complex (MHC) class I stabilization assay on Transporter Associated with Antigen Processing (TAP)-deficient T2 cells.\n\nC. The F$\\rightarrow$D substitution at P$1$ will have minimal effect because class II binding is driven primarily by peptide flanking residues; validate by enzyme-linked immunospot (ELISpot) for interferon-$\\gamma$ after loading peptide on any antigen-presenting cell regardless of HLA type.\n\nD. The F$\\rightarrow$D substitution at P$1$ will eliminate T cell recognition but not MHC binding because P$1$ affects only T cell receptor contacts; validate by high-throughput T cell receptor (TCR) repertoire sequencing after stimulation with the substituted peptide.", "solution": "The problem statement is evaluated as scientifically sound, well-posed, and objective. It provides a specific, realistic scenario in molecular immunology based on established principles of Major Histocompatibility Complex (MHC)-peptide interaction. All givens are consistent and sufficient to derive a logical conclusion.\n\n**1. Prediction of the Substitution's Effect on Binding**\n\nThe core of the problem lies in understanding the biophysical principles governing peptide binding to MHC class II molecules. The binding affinity of a peptide to an MHC molecule is largely determined by the interactions between specific amino acid side chains of the peptide, known as anchor residues, and complementary pockets within the MHC's peptide-binding groove.\n\n*   **Original Peptide Interaction:** The problem states that the peptide core is \"VFYLMGRTK\" and that phenylalanine (F) occupies the P1 anchor position. Phenylalanine is an amino acid with a large, aromatic, and strongly hydrophobic side chain (a benzyl group). The MHC allele is HLA-DRB1*04:01, whose P1 pocket is described as \"deep and largely hydrophobic\". The favorable interaction between the hydrophobic side chain of the F residue at P1 and the nonpolar environment of the P1 pocket is a critical anchoring interaction that contributes substantially to the overall stability of the peptide-MHC complex. This is a classic example of the hydrophobic effect driving molecular recognition.\n\n*   **The Engineered Substitution:** The Phenylalanine (F) at the P1 position is replaced by Aspartate (D). Aspartate's side chain is $-\\text{CH}_2\\text{COOH}$. At physiological pH (approximately 7.4), the carboxylic acid group is deprotonated to a carboxylate ($-\\text{CH}_2\\text{COO}^-$), making the side chain negatively charged and highly hydrophilic.\n\n*   **Consequence of the Substitution:** The substitution of F with D results in the placement of a small, negatively charged, hydrophilic side chain into a deep, hydrophobic pocket. This substitution is energetically highly unfavorable for several reasons:\n    1.  **Loss of Favorable Hydrophobic Interactions:** The significant favorable contribution to binding energy from the burial of the large hydrophobic Phenylalanine side chain is completely lost.\n    2.  **Introduction of Unfavorable Interactions:** Forcing a charged group (Aspartate's carboxylate) into a nonpolar (hydrophobic) environment incurs a substantial energetic penalty, known as a desolvation penalty. The charged group is much more stable when solvated by polar water molecules than when enclosed in a nonpolar protein pocket.\n    3.  **Lack of Compensating Interactions:** The hydrophobic P1 pocket lacks positively charged residues that could form a stabilizing salt bridge with the negatively charged Aspartate.\n\n*   **Conclusion:** Based on these first principles of molecular interactions, the F $\\rightarrow$ D substitution at the P1 anchor position is predicted to severely disrupt or completely abrogate the binding of the peptide to the HLA-DRB1*04:01 molecule. The effect will be a marked reduction in binding affinity.\n\n**2. Selection of the Validating Experimental Assay**\n\nThe task requires selecting an assay to **directly validate** the prediction about peptide **binding**. This means the assay must measure the physical interaction between the peptide and the MHC molecule itself, quantitatively, and in isolation from other biological processes like T cell recognition.\n\n*   **An ideal assay** would use purified components (peptide and MHC molecule) and provide a quantitative measure of affinity, such as an equilibrium dissociation constant ($K_D$) or a half-maximal inhibitory concentration ($IC_{50}$).\n\n**3. Evaluation of Provided Options**\n\n**A. The F$\\rightarrow$D substitution at P$1$ will markedly reduce peptide binding to HLA-DRB1*04:01 due to loss of a hydrophobic anchor in a hydrophobic pocket; validate by an in vitro competitive binding assay using purified HLA-DRB1*04:01 and a labeled high-affinity reference peptide to measure the half-maximal inhibitory concentration ($IC_{50}$).**\n\n*   **Prediction:** The prediction of markedly reduced binding and the reasoning (loss of a hydrophobic anchor) are perfectly aligned with the biophysical principles derived above.\n*   **Assay:** An in vitro competitive binding assay is the gold standard for directly measuring the binding affinity of an unlabeled peptide to an MHC molecule. It uses purified components (HLA-DRB1*04:01), directly testing the interaction in question. It is quantitative, yielding an $IC_{50}$ value. A large increase in the $IC_{50}$ for the substituted peptide compared to the original would directly validate the prediction of reduced binding.\n*   **Verdict:** **Correct**.\n\n**B. The F$\\rightarrow$D substitution at P$1$ will increase peptide binding to HLA-DRB1*04:01 by enabling a favorable salt bridge within the P$1$ pocket; validate by a Major Histocompatibility Complex (MHC) class I stabilization assay on Transporter Associated with Antigen Processing (TAP)-deficient T2 cells.**\n\n*   **Prediction:** The prediction of increased binding is incorrect. The reasoning is flawed; a salt bridge cannot form in a hydrophobic pocket that lacks a counter-charge.\n*   **Assay:** The proposed assay is fundamentally incorrect for this problem. T2 cell stabilization assays are used to measure peptide binding to MHC **class I** molecules, not MHC **class II** molecules like HLA-DRB1*04:01. The antigen processing and loading pathways for class I and class II are distinct.\n*   **Verdict:** **Incorrect**.\n\n**C. The F$\\rightarrow$D substitution at P$1$ will have minimal effect because class II binding is driven primarily by peptide flanking residues; validate by enzyme-linked immunospot (ELISpot) for interferon-$\\gamma$ after loading peptide on any antigen-presenting cell regardless of HLA type.**\n\n*   **Prediction:** The prediction of minimal effect is incorrect. Core anchor residues, like P1, are the primary determinants of binding affinity for most MHC molecules, not the flanking residues.\n*   **Assay:** The proposed assay has two major flaws. First, an ELISpot assay for IFN-$\\gamma$ measures T cell activation, which is an indirect and downstream consequence of peptide-MHC binding. It does not directly measure the binding event itself. Second, the stipulation to use \"any antigen-presenting cell regardless of HLA type\" is fundamentally wrong, as peptide binding is exquisitely specific to the particular HLA allele (HLA-DRB1*04:01 in this case).\n*   **Verdict:** **Incorrect**.\n\n**D. The F$\\rightarrow$D substitution at P$1$ will eliminate T cell recognition but not MHC binding because P$1$ affects only T cell receptor contacts; validate by high-throughput T cell receptor (TCR) repertoire sequencing after stimulation with the substituted peptide.**\n\n*   **Prediction:** The reasoning is incorrect. The P1 position is a canonical anchor residue that points into the MHC groove and is a primary determinant of MHC binding, not T cell receptor (TCR) contact. Residues pointing away from the groove are the primary TCR contacts. The substitution is therefore expected to have a major effect on MHC binding.\n*   **Assay:** Similar to option C, TCR sequencing measures the T cell response, not the direct peptide-MHC binding event. It is an indirect assay unsuitable for directly testing the prediction about binding affinity.\n*   **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4605128"}, {"introduction": "The principles of peptide-MHC binding, such as the importance of anchor residues, can be systematized into powerful predictive models used in immunoinformatics. This problem provides a hands-on opportunity to apply a quantitative scoring motif to predict how strongly a peptide binds to an $MHC$ class $I$ molecule. By calculating a binding score and converting it to a probability, you will gain practical insight into how potential T cell epitopes are identified for applications like vaccine development [@problem_id:4605170].", "problem": "A cytotoxic T lymphocyte recognizes peptides bound to Major Histocompatibility Complex (MHC) class I molecules on infected cells. Human Leukocyte Antigen (HLA) class I alleles, such as Human Leukocyte Antigen-B*07:02 (HLA-B*07:02), bind peptides typically of length $8$–$10$ with critical “anchor” residues that fit into conserved pockets of the binding groove. For HLA-B*07:02, literature and experimental consensus support anchors at peptide position $2$ (the B-pocket) and the C-terminal position (position $\\Omega$; for a $9$-mer, position $9$) in the F-pocket. A motif-based position-specific scoring approach can approximate binding likelihood by summing residue-specific contributions at anchor and auxiliary positions, followed by a logistic transform to map the score to a probability.\n\nConsider the $9$-mer peptide sequence “APRGVYELI” and the following scientifically plausible motif preferences for HLA-B*07:02:\n\n- Anchor position $2$ (B-pocket) contributions $w_{2}(\\cdot)$:\n  - $w_{2}(\\text{P}) = 2.0$, $w_{2}(\\text{A}) = 0.5$, $w_{2}(\\text{S}) = 0.3$, all other residues contribute $0$.\n- Anchor position $9$ (F-pocket; position $\\Omega$ for a $9$-mer) contributions $w_{9}(\\cdot)$:\n  - $w_{9}(\\text{L}) = 1.8$, $w_{9}(\\text{I}) = 1.5$, $w_{9}(\\text{F}) = 1.6$, $w_{9}(\\text{V}) = 1.2$, $w_{9}(\\text{M}) = 1.4$, all other residues contribute $0$.\n- Auxiliary position $3$ contributions $w_{3}(\\cdot)$:\n  - $w_{3}(\\text{R}) = 0.4$, $w_{3}(\\text{K}) = 0.3$, all other residues contribute $0$.\n- Auxiliary position $5$ hydrophobic preference $w_{5}(\\cdot)$:\n  - For $\\{\\text{A}, \\text{V}, \\text{L}, \\text{I}, \\text{F}, \\text{M}, \\text{Y}\\}$, $w_{5}(\\cdot) = 0.2$, otherwise $0$.\n\nDefine the motif match score $S$ as the sum of these position-specific weights over the peptide:\n$$\nS \\equiv w_{2}(X_{2}) + w_{9}(X_{9}) + w_{3}(X_{3}) + w_{5}(X_{5}),\n$$\nwhere $X_{i}$ denotes the residue at position $i$ of the peptide.\n\nMap $S$ to an estimated binding probability $p$ using a logistic function calibrated for a motif-based classifier:\n$$\np = \\frac{1}{1 + \\exp\\!\\big(-(\\alpha S + \\beta)\\big)},\n$$\nwith calibration constants $\\alpha = 0.70$ and $\\beta = -1.00$.\n\nTasks:\n- Using fundamental definitions of MHC class I anchor positions and the provided motif preferences, identify the most likely anchor residues in the peptide “APRGVYELI”.\n- Compute the motif match score $S$ for this peptide.\n- Compute the binding probability $p$ using the logistic mapping above.\n\nRound your final numerical answer for $p$ to four significant figures. Express your final answer as a pure number without any units.", "solution": "The recognition of peptides by Major Histocompatibility Complex (MHC) class I relies on anchor residues occupying conserved pockets, particularly the B-pocket at position $2$ and the F-pocket at position $\\Omega$ (position $9$ for a $9$-mer peptide). For Human Leukocyte Antigen-B*07:02 (HLA-B*07:02), well-established preferences include a strong preference for proline at position $2$, and hydrophobic/aromatic residues such as leucine, isoleucine, valine, phenylalanine, and methionine at the C-terminal position.\n\nStep $1$: Identify anchor residues from the peptide sequence.\n\nThe peptide is “APRGVYELI”, which we index as:\n- $X_{1} = \\text{A}$,\n- $X_{2} = \\text{P}$,\n- $X_{3} = \\text{R}$,\n- $X_{4} = \\text{G}$,\n- $X_{5} = \\text{V}$,\n- $X_{6} = \\text{Y}$,\n- $X_{7} = \\text{E}$,\n- $X_{8} = \\text{L}$,\n- $X_{9} = \\text{I}$.\n\nBy motif definition, the anchor positions for HLA-B*07:02 in a $9$-mer are positions $2$ and $9$. Thus, the most likely anchor residues in this peptide are $X_{2} = \\text{P}$ and $X_{9} = \\text{I}$.\n\nStep $2$: Compute the motif match score $S$ using the provided weights.\n\nWe use\n$$\nS = w_{2}(X_{2}) + w_{9}(X_{9}) + w_{3}(X_{3}) + w_{5}(X_{5}).\n$$\n\nEvaluate each term:\n- At position $2$: $X_{2} = \\text{P}$, so $w_{2}(\\text{P}) = 2.0$.\n- At position $9$: $X_{9} = \\text{I}$, so $w_{9}(\\text{I}) = 1.5$.\n- At position $3$: $X_{3} = \\text{R}$, so $w_{3}(\\text{R}) = 0.4$.\n- At position $5$: $X_{5} = \\text{V}$, which is hydrophobic and in the specified set, so $w_{5}(\\text{V}) = 0.2$.\n\nSum the contributions:\n$$\nS = 2.0 + 1.5 + 0.4 + 0.2 = 4.1.\n$$\n\nStep $3$: Map $S$ to the binding probability $p$ using the logistic function with $\\alpha = 0.70$ and $\\beta = -1.00$.\n\nCompute the linear predictor:\n$$\n\\alpha S + \\beta = 0.70 \\times 4.1 + (-1.00) = 2.87 - 1.00 = 1.87.\n$$\n\nThen compute\n$$\np = \\frac{1}{1 + \\exp\\!\\big(-(1.87)\\big)} = \\frac{1}{1 + \\exp(-1.87)}.\n$$\n\nEvaluate $\\exp(-1.87)$. Using $\\exp(1.87) \\approx 6.488296394$, we have\n$$\n\\exp(-1.87) \\approx \\frac{1}{6.488296394} \\approx 0.154124.\n$$\nTherefore,\n$$\np \\approx \\frac{1}{1 + 0.154124} = \\frac{1}{1.154124} \\approx 0.86645.\n$$\n\nRounding to four significant figures gives\n$$\np \\approx 0.8665.\n$$\n\nThus, the final rounded binding probability is $0.8665$.", "answer": "$$\\boxed{0.8665}$$", "id": "4605170"}]}